Wall Street Analysts Believe Intellia Therapeutics, Inc. (NTLA) Could Rally 145.32%: Here's is How to TradeZacks Investment Research • 02/06/23
Does Intellia Therapeutics, Inc. (NTLA) Have the Potential to Rally 185.4% as Wall Street Analysts Expect?Zacks Investment Research • 01/13/23
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary AngioedemaGlobeNewsWire • 01/11/23
Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key MilestonesGlobeNewsWire • 01/05/23
SparingVision's lead asset SPVN06 clears IND application in the US for the treatment of retinitis pigmentosaGlobeNewsWire • 12/01/22
Intellia Therapeutics Presents New Interim Data from First-in-Human Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the American College of Allergy, Asthma & Immunology 2022 Annual Scientific MeetingGlobeNewsWire • 11/12/22
Intellia Presents Updated Interim Data from the Cardiomyopathy Arm of Ongoing Phase 1 Study of NTLA-2001, an Investigational CRISPR Therapy for the Treatment of Transthyretin (ATTR) Amyloidosis at the American Heart Association Scientific Sessions 2022GlobeNewsWire • 11/05/22
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue EstimatesZacks Investment Research • 11/03/22
Intellia Therapeutics, Inc. (NTLA) Q3 2022 Results - Earnings Call TranscriptSeeking Alpha • 11/03/22